Population-wide assessment of human health is challenging because of intrinsic genetic diversity complicated by age and other non-genetic factors, such as exposure to environmental stressors. To assess human responses to drugs and toxicants, we develop functional in vitro cell-based assays using highly proliferative primary human cells non-invasively isolated from human tissues.
To study the diversity of responses to drugs and toxicants we compile libraries of Highly Proliferative Primary Cells by growing them in culture and cryopreserving for many years, thus enabling to conduct hundreds of assays from a single donor.
Endothelial Colony Forming Cells
CELL BASED TOXICOLOGY
Donor-Derived Progenitor Cells for Population-Wide Toxicity Testing
Environmental toxicants affect people differently. A substance harmless to one person can be toxic to another because of genetics, or previous experiences, or both. To identify such vulnerable people we are developing special assay platform utilizing donor-derived progenitor cells.
We develop an assay platform utilizing donor-specific endothelial progenitor cells as a proxy to test individual sensitivity to ionizing radiation (IR). IR is known to cause long-term complications. In our method, individual IR sensitivity is correlated to an in vitro response to radiation of endothelial progenitor cells, also called endothelial colony forming cells (ECFCs), which critically contribute to the healing of injured tissues. ECFC recruitment, proliferation, and differentiation have been proposed to be a key to tissue recovery after radiation-induced damage. Our assay platform will help to test individual susceptibility to radiation-mediated damage and enable the discovery of novel radioprotectors.
MEET THE CREATIVE SCIENTIST
Founder & CEO, Business and Scientific Leadership
Chief Scientist, Cell-Based Assay Development
Collaborator, Molecular Biology Product Development
Collaborator, High Content Imaging